Genervon Biopharmaceuticals

What Genervon Biopharmaceuticals does

Genervon Biopharmaceuticals is a privately held, clinical-stage biopharmaceutical company founded circa 2003 in Pasadena, California, that is developing GM6 — a 6-amino-acid cationic cell-penetrating peptide analog of Motoneuronotrophic Factor (MNTF), an endogenous regulator of human nervous system development. GM6 is designed to cross the blood-brain barrier and simultaneously modulate multiple pathological pathways (Aβ amyloid, tau, TDP-43, fibrinogen, inflammation) associated with neurodegenerative diseases. The company is pursuing six CNS indications: ALS, Parkinson's disease, Alzheimer's disease, multiple sclerosis, spinal cord injury, and stroke, with GM6/GM604 having completed Phase 1 and Phase 2A clinical trials in ALS and Parkinson's, and being designated as Phase 3 ready for ALS.

The company's technology platform is anchored by composition-of-matter and method-of-treatment patents worldwide covering MNTF, GM6, and related peptide analogs, including methods for inducing stem cell differentiation into motor neurons. GM6 has received orphan drug designation in both the U.S. and Europe, along with FDA fast-track designation for ALS treatment. The drug exhibits strong stability (120 months at -20°C), low-cost GMP manufacturing via solid-phase synthesis, and a favorable safety profile consistent with its endogenous human origin.

Genervon's business model is partnership-driven: the company has no current revenue and is actively seeking pharmaceutical partners to co-develop and commercialize GM6. It conducts clinical trials at leading academic medical centers including Massachusetts General Hospital and Columbia Presbyterian Medical Center. The company maintains a small team (1-10 employees), is led by founder Winston Ko (Chairman/CEO), and has operated for over 20 years without disclosed external institutional funding, suggesting bootstrapped or privately financed operations.

Name

Genervon Biopharmaceuticals

Legal name

Genervon Biopharmaceuticals, LLC

Website

https://genervon.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

Genervon Biopharmaceuticals is a clinical-stage, privately held biopharmaceutical company developing GM6, a multi-target blood-brain-barrier-penetrating peptide for neurodegenerative diseases including ALS, Parkinson's, and Alzheimer's, seeking pharmaceutical partners for late-stage development and commercialization.

Ownership category

akta.pro rank

Headquarters

HQ city

Pasadena

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Drug Development and Commercialization: As a clinical-stage biopharmaceutical company, Genervon currently has no revenue. The company is developing GM6 for multiple neurodegenerative indications (ALS, PD, AD, MS, Stroke, SCI) and plans to commercialize through partnership with pharmaceutical companies or independently upon regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Genervon is a clinical-stage biopharmaceutical company developing GM6, a 6-amino-acid cationic cell-penetrating peptide analog of the endogenous developmental regulator Motoneuronotrophic Factor (MNTF), for neurodegenerative and CNS indications. The company's lead candidate (and indication-specific designations GM604 for ALS, GM608 for Parkinson's, GM602 for stroke) penetrates the blood-brain barrier and modulates multiple defective pathways including Aβ, tau, TDP-43, SOD1, and neuroinflammation to deliver neuroprotective and neuroregenerative effects. GM6 has completed Phase 1 and Phase 2A trials in ALS and Parkinson's disease, has FDA orphan drug (U.S. and Europe) and fast-track designations for ALS, and is positioned for late-stage trials across ALS, PD, AD, MS, SCI, and stroke.

Product overview

Genervon Biopharmaceuticals is a clinical-stage biopharmaceutical company developing GM6-based therapeutics for neurodegenerative diseases. The core technology platform centers on Motoneuronotrophic Factor (MNTF), a naturally occurring regulator of nervous system development, from which GM6 (a 6-amino-acid active peptide analog) was derived. The product portfolio includes GM6 (general pipeline designation), GM604 (ALS indication), GM608 (Parkinson's disease indication), and GM602 (stroke indication). GM6 has completed Phase 1 and Phase 2A trials, demonstrating safety, blood-brain barrier penetration, and modulation of key biomarkers. The company holds many composition-of-matter and method-of-treatment patents worldwide. Genervon is planning late-stage trials for ALS (Phase 3 ready), PD (Phase 2b ready), AD (Phase 2 ready), MS (Phase 2 ready), SCI (Phase 2 ready), and Stroke (Phase 2b ready).

Differentiator

Problem solved

Functional benefit

Products and services

• GM6 GM6 is a 6-amino-acid active analog peptide of Motoneuronotrophic Factor (MNTF), Genervon's lead drug candidate designed to treat neurodegenerative diseases through multi-target mechanisms. It penetrates the blood-brain barrier and has demonstrated neuroprotective and disease-modifying effects in models of ALS, Parkinson's disease, Alzheimer's disease, multiple sclerosis, spinal cord injury, and stroke, and has completed Phase 1 and Phase 2A clinical trials for ALS and Parkinson's disease.
• GM604 GM604 is the indication-specific designation of Genervon's GM6 peptide for Amyotrophic Lateral Sclerosis (ALS). It received orphan drug designation in the U.S. and Europe, and its Phase 2A trial showed favorable shifts in plasma biomarkers (SOD1, Tau, TDP-43) with statistical significance and positive clinical outcome signals. The asset is Phase 3 ready.
• GM608 GM608 is the indication-specific designation of Genervon's GM6 peptide for Parkinson's disease, designated for the GAP-PD (Phase 2A Study of GM608 in Mild to Moderate Parkinson Disease) clinical trial. The Phase 2A trial demonstrated safety and statistically significant increases in BDNF neuroprotective biomarker, with signals of slowing clinical worsening of PD.
• GM602 GM602 is Genervon's drug candidate for acute ischemic stroke, studied in the GMAIS (Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours) clinical trial registered on ClinicalTrials.gov. GM6 demonstrated dose-dependent reduction in infarct size and improved neurological deficit scores in MCAO stroke models.

Quantifiable outcome

• ALS Phase 2A: Mean change in slope for plasma TDP-43 from baseline to week 12 was -3.513 pg/ml (34% decrease) in GM6-treated groups vs +0.493 pg/ml (6% increase) in placebo (p=0.0078)
• +6 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered minor and core.

• American Society for Experimental Neurotherapeutics (ASENT)minorGTM or Marketing Partner · 1 January 2019Genervon presented research data at ASENT Annual Meetings (2019, 2021, 2022, 2023) showcasing GM6 clinical and preclinical data.
• Massachusetts General HospitalcoreStrategic or Co-development PartnerPhase 2A ALS clinical trial conducted at Massachusetts General Hospital, one of the leading research institutions in the U.S.
• Columbia Presbyterian Medical CentercoreStrategic or Co-development PartnerPhase 2A ALS clinical trial conducted at Columbia Presbyterian Medical Center, a leading academic medical center.

Scale indicators4 records

Recent moves6 records

Expansion highlights3 records

Broad incumbents

• Biogen: Major neurodegenerative disease player with an established ALS franchise (Spinraza, Riliuzole successor programs). Directly comparable as a competing ALS/neurodegeneration developer with vastly greater scale and capital, serving the same patient populations targeted by GM604/GM6.
• Denali Therapeutics: Well-capitalized biotech developing therapies for ALS, Parkinson's, Alzheimer's and other neurodegenerative diseases. Comparable as a broad neurodegeneration platform pursuing multiple CNS indications at scale, representing the partnership archetype Genervon is seeking.
• Voyager Therapeutics: Clinical-stage gene therapy company with CNS programs including Parkinson's and ALS. Comparable as a small-cap CNS biotech targeting the same neurodegenerative indications as GM6/GM604 with a different modality (gene therapy vs peptide).

Direct peers

• Ionis Pharmaceuticals: Antisense oligonucleotide platform developer with multiple CNS programs including ALS and neurodegenerative disease assets. Comparable as a platform-based CNS rare-disease biotech pursuing multi-program pipeline leveraging a single core technology approach.
• Cytokinetics: Late-stage clinical biotech with a direct ALS drug candidate (reldesemtiv) in pivotal trials. Directly comparable as a small-cap public clinical-stage peer developing neuro/ALS therapeutics through clinical partnerships.
• AB Science: Clinical-stage pharmaceutical company developing masitinib for ALS and other neurodegenerative indications. Comparable as a direct ALS competitor with similar disease-modification thesis and orphan-style regulatory positioning.
• Medicinova: Clinical-stage biopharma with MN-166 (ibudilast) in ALS, MS and other CNS indications. Comparable as a small-cap clinical biotech repurposing/advancing CNS drugs across multiple neurodegenerative programs like Genervon.
• Neuralstem: Clinical-stage biotech developing cell therapy and small molecule treatments for ALS and other CNS conditions. Comparable as a small clinical-stage ALS competitor with a neuroprotective/neuro-regenerative therapeutic thesis.
• Orphazyme: Rare neurodegenerative disease biotech developing heat-shock protein therapies for ALS, MS and other indications. Comparable as a clinical-stage rare-CNS-disease developer pursuing multiple orphan indications with a single platform approach.

Emerging players

• Helixmith: Clinical-stage biotech with CNS programs including Engensis for ALS and other neurodegenerative indications. Comparable as a smaller competing clinical-stage developer of disease-modifying CNS therapies targeting ALS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genervon Biopharmaceuticals